

FILE COPY

Sheet 01 of 15

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1101P2Serial No.  
09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Ashkenazi et al.Filing Date  
15 Sep 1999Group  
1643 1646 #4

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
cu	*	1 3,691,016	12.09.72	Patel, R.			
	*	2 3,969,287	13.07.76	Jaworek et al.			
	*	3 4,179,337	18.12.79	Davis et al.			
	*	4 4,195,128	25.03.80	Hildebrand et al.			
	*	5 4,229,537	21.10.80	Hodgins et al.			
	*	6 4,247,642	27.01.81	Hirohara et al.			
	*	7 4,301,144	17.11.81	Iwashita et al.			
	*	8 4,330,440	18.05.82	Ayers et al.			
	*	9 4,342,566	03.08.82	Theofilopoulos et al.			
	*	10 4,399,216	16.08.83	Axel et al.			
	*	11 4,419,446	06.12.83	Howley et al.			
	*	12 4,496,689	29.01.85	Mitra, G.			
	*	13 4,601,978	22.07.86	Karin, M.			
	*	14 4,640,835	03.02.87	Shimizu et al.			
	*	15 4,670,417	02.06.87	Iwasaki et al.			
	*	16 4,676,980	30.06.87	Segal et al.			
	*	17 4,736,866	12.04.88	Leder et al.			
	*	18 4,791,192	13.12.88	Nakagawa et al.			
	*	19 4,816,567	28.03.89	Cabilly et al.			
	*	20 4,855,235	08.08.89	Takahashi et al.			
	*	21 4,870,009	26.09.89	Evans et al.			
	*	22 4,965,199	23.10.90	Capon et al.			
	*	23 5,010,182	23.04.91	Brake et al.			
	*	24 5,153,118	06.10.92	Wright, Jr. et al.			
	*	25 5,158,885	27.10.92	Bradstock et al.			
cu	*	26 5,364,934	15.11.94	Drayna et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
cu	*	27 036,776	30.09.81	EPO				
	*	28 073,657	09.03.83	EPO				
	*	29 117,058	29.08.84	EPO				
	*	30 117,060	29.08.84	EPO				
	*	31 125,023 A1	14.11.84	EPO				
	*	32 173,494	05.03.86	EPO				
	*	33 278,776	17.08.88	EPO				

Examiner

Cham-ke

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643-1646

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
CU	* 34	307,247	15.03.89	EPO				
	* 35	321,196	21.06.89	EPO				
	* 36	362,179	04.04.90	EPO				
	* 37	417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	* 38	266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)				
	* 39	WO 87/05330	11.09.87	PCT				
	* 40	WO 89/02922	06.04.89	PCT				
	* 41	WO 89/05859	29.06.89	PCT				
	* 42	WO 90/13646	15.11.90	PCT				
	* 43	WO 91/00358	10.01.91	PCT				
	* 44	WO 91/00360	10.01.91	PCT				
	* 45	WO 91/08291	13.06.91	PCT				
	* 46	WO 92/20373	26.11.92	PCT				
	* 47	WO 93/08829	13.05.93	PCT				
	* 48	WO 94/04679	03.03.94	PCT				
	* 49	WO 94/04690	03.03.94	PCT				
	* 50	WO 94/29348	22.12.94	PCT				
	* 51	WO 95/10540	20.04.95	PCT				
	* 52	WO 95/11301	27.04.95	PCT				
	* 53	WO 95/31544	23.11.95	PCT				
	* 54	WO 97/01633	16.01.97	PCT				
	* 55	WO 97/25428	17.07.97	PCT				
CU	* 56	2,211,504	05.07.89	UNITED KINGDOM				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 57	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for $\mu$ , $\alpha$ , $\gamma 1$ , $\gamma 2a$ , and $\gamma 3$ chains" <u>Biochemistry</u> 19:2711-2719 (1980)
* 58	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
* 59	Aplin et al., "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)
* 60	Ashkenazi and Chamow, "Immunoconjugates: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995)
* 61	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoconjugate" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (Dec 1991)
* 62	<del>Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium, Dicke et al., University of Texas M.D. Anderson Hospital (1987)</del>
* 63	Baldwin, "The NF- $\kappa$ B and I $\kappa$ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-681 (1996)

Examiner

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643 1646

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- an \* 64 Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" Cell 33:729-740 (July 1983)
- \* 65 Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF $\beta$  Complex: Implications for TNF Receptor Activation" Cell 73:431-445 (1993)
- \* 66 Barr et al., "Apoptosis and Its Role in Human Disease" Bio/Technology 12:487-493 (1994)
- \* 67 Bianchi et al., "Transformation of the yeast *Kluyveromyces lactis* by New Vectors Derived from the 1.6  $\mu$ m Circular Plasmid pKD1" Curr. Genet. 12:185-192 (1987)
- \* 68 "BLAST Results A-1 - A-47" (GenBank)
- \* 69 "BLAST Results B-1 - B-31" (GenBank, -EST)
- an \* 70 "BLAST Results C-1 - C-36" (Patent)
- \* 71 ~~"BLAST Results D-1 - D-40" (Dayhoff patent)~~
- \* 72 ~~"BLAST Results E-1 - E-25" (Human -pat)~~
- \* 73 ~~"BLAST Results F-1 - F-52" (Dayhoff)~~
- an \* 74 Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" Immunity 6:79-88 (1997)
- \* 75 Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" The Journal of Immunology 147(1):86-95 (1991)
- \* 76 Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" Cell 85:803-815 (1996)
- \* 77 Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" Journal of Biological Chemistry 270:387-391 (1995)
- \* 78 Boulianne et al., "Production of functional chimaeric mouse/human antibody" Nature 312:643-646 (December 13, 1984)
- \* 79 Bradley, "Production and Analysis of Chimaeric Mice" Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
- \* 80 Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990)
- \* 81 Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" Monoclonal Antibody Production Techniques and Applications, New York:Marcel Dekker, Inc. pps. 51-63 (1987)
- \* 82 Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" Cell 87:845-855 (Nov 29, 1996)
- an \* 83 Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" Year in Immunology 7:33-40 (1993)

Examiner

C. M. M. K.

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396710

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/1646

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

an	* 84	Byrn et al., "Biological Properties of a CD4 Immunoaderhin" <u>Nature</u> 344:667-670 (April 12, 1990)
	* 85	Canaani et al., "Regulated Expression of Human Interferon $\beta$ 1 Gene After Transduction into Cultured Mouse and Rabbit Cells" <u>Proc. Natl. Acad. Sci. USA</u> 79:5166-5170 (September 1982)
	* 86	Capon et al., "Designing CD4 Immunoaderhins for AIDS Therapy" <u>Nature</u> 337:525-531 (February 9, 1989)
	* 87	Caron et al., "Engineered humanized dimeric forms of IgG are more effective antibodies" <u>Journal of Experimental Medicine</u> 176(4):1191-1195 (Oct. 1, 1992)
	* 88	Carter et al., "Humanization of an anti-p185 <sup>HER2</sup> antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)
an	* 89	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)
	* 90	Chamow et al., "A Humanized, Bispecific Immunoaderhin-Antibody That Retargets CD3 <sup>+</sup> Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)
an	* 91	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)
cu	* 92	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-KB Pathway" <u>Immunity</u> 7:821-830 (1997)
	* 93	<u>Chemotherapy Service Ed.</u> , M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)
cu	* 94	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)
	* 95	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)
	* 96	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)
	* 97	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)
	* 98	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
	* 99	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)
	*100	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
	*101	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)
an	*102	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)
	*103	Cohen, "Programmed Cell Death in the Immune System" <u>Advances in Immunol.</u> 50:55-85 (1991)

Examiner

Charles N. K.

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/1646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

aw	*104	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., New York:Alan R. Liss, Inc. pps. 77-96 (1985)
aw	*105	Creighton,, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)
	*106	<del>Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" <u>Methods in Cell Biol.</u> 41:15-38 (1994)</del>
aw	*107	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)
	*108	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- $\gamma$ " <u>European Journal of Immunology</u> 17:689-693 (1987)
	*109	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)
	*110	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (Oct 6, 1997)
	*111	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Mol. Appl. Gen.</u> 1:561-573 (1982)
	*112	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press pps. 1-16;133-142 (1995)
	*113	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin $\mu$ chain cDNA from B cells and mouse-human hybridomas" <u>Proc. Natl. Acad. Sci. USA</u> 77(10):6027-6031 (1980)
aw	*114	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" <u>Journal of Biological Chemistry</u> 257:3105-3109 (1982)
	*115	<del>Eck and Sprang, "The structure of tumor necrosis factor-<math>\alpha</math> at 2.6 A resolution" <u>Journal of Biological Chemistry</u> 264(29):17595-17604 (1989)</del>
	*116	<del>Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-<math>\beta</math>) at 1.9-A Resolution" <u>J. Bio. Chem.</u> 267:2119-2122 (1992)</del>
aw	*117	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)
	*118	Ellis, "Recognition of HLA-B27 and Related Antigen by a Monoclonal Antibody" <u>Human Immunology</u> 5:49-59 (1982)
	*119	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand Trail" <u>Journal of Interferon and Cytokine Research</u> (Abstract No. 2.17 from the 7th Intl. Tumor Necrosis Factor Congress May 17-21) 18(5):A-47 (May 1998)
	*120	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)
aw	*121	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular &amp; Cellular Biology</u> 5:3610-3616 (1985)
	*122	<del>Fadok et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages" <u>J. Immunol.</u> 148:2207-2216 (1992)</del>
aw	*123	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)

Examiner

Chen M. K.

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643 1646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Cur	*124	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular &amp; Cellular Biology</u> 8:2159-2165 (1988)
Cur	*125	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" <u>Nature</u> 273:113-120 (May 11, 1978)
	*126	Fishwild et al., "High-avidity human IgG monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14(7):845-851 (Jul 1996)
Cur	*127	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <i>Kluyveromyces</i> Yeasts" <u>Bio/Technology</u> 9:968-975 (1991)
	*128	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)
	*129	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)
	*130	Gething et al., "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)
	*131	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells" <u>Proc. Natl. Acad. Sci. USA</u> 94(14):7509-7514 (Jul 8, 1997)
	*132	Glassy, M., "Production methods for generating human monoclonal antibodies" <u>Human Antibodies &amp; Hybridomas</u> 4(4):154-165 (Oct 1993)
	*133	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)
	*134	Goeddel et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)
	*135	Goeddel et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> " <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)
	*136	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular &amp; Cellular Biology</u> 11:3020-3026 (1991)
	*137	Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" <u>Proc. Natl. Acad. Sci. USA</u> 79:6777-6781 (November 1982)
	*138	Gough et al., "Molecular cloning of seven mouse immunoglobulin $\kappa$ chain messenger ribonucleic acids" <u>Biochemistry</u> 19:2702-2710 (1980)
	*139	Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
	*140	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)
	*141	Gray et al., "Expression of Human Immune Interferon cDNA in <i>E. coli</i> and Monkey Cells" <u>Nature</u> 295:503-508 (February 11, 1982)
	*142	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" <u>Gene</u> 18:355-360 (1982)
Cur	*143	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)

Examiner

Clem M. K.

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/1646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

144	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
145	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York: Pergamon Press Vol. 7:149-167 (1968)
146	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)
147	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF $\alpha$ )" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
148	Holland et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)
149	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V <sub>H</sub> gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
150	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
151	Hsiao et al., "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)
152	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)
153	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)
154	Iliades et al., "Triabodies: single chain Fv fragments without a linker form trivalent trimers" <u>FEBS Letters</u> 409(3):437-441 (Jun 16, 1997)
155	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
156	Jakovovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" <u>Proc. Natl. Acad. Sci. USA</u> 90:2551-2555 (March 1993)
157	Jakovovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" <u>Nature</u> 362:255-258 (March 18, 1993)
158	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (November 21, 1986)
159	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
160	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977)
161	Jones, Y., "Cytokine Receptor Complexes Verses Cell Adhesion Interactions - Upping the Affinity" (Abstract no. M11.OA.002 presented at the XVIIth IUCr Congress & General Assembly held in Glasgow, Scotland on August 4th-13th, 1999.) pps. 133
162	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)
163	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region" <u>Gene</u> 7:141-152 (1979)

Examiner

C. A. N. H. J.

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CW	*164	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
CW	*165	Kohler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)
CW	*166	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
CW	*167	Koopman et al., "Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis" <u>Blood</u> 84:1415-1420 (1994)
CW	*168	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer" <u>Protein Engineering</u> 10(4):423-433 (Apr 1997)
CW	*169	Kozak, "An analysis of vertebrate mRNA sequences: intimations of translational control" <u>Journal of Cell Biology</u> 115:887-903 (1991)
CW	*170	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)
CW	*171	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
CW	*172	<del>Kyriakis et al., "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation" <u>Journal of Biological Chemistry</u> 271:24313-24316 (1996)</del>
CW	*173	Laimins et al., "Osmotic Control of kdp Operon Expression in Escherichia Coli" <u>Proc. Natl. Acad. Sci. USA</u> 78(1):464-468 (Jan 1981)
CW	*174	Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P432) p. 115 (1991)
CW	*175	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
CW	*176	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)
CW	*177	LIFESEQ Database EST-Sequence-Reference-#1 DO NOT PRINT
CW	*178	LIFESEQ Database EST-Sequence-Reference-#2 DO NOT PRINT
CW	*179	<del>Liu et al., "Dissection of TNF Receptor 1 Effector Functions: JNK Activation is not Linked to Apoptosis While NF-<math>\kappa</math>B Activation Prevents Cell Death" <u>Cell</u> 87:565-576 (1996)</del>
CW	*180	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (April 20, 1990)
CW	*181	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)
CW	*182	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" <u>Molecular &amp; Cellular Biology</u> 3(6):1108-1122 (June 1983)
CW	*183	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)

Examiner

Paw M. G.

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643-1646

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Cut	*184	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (Oct 10, 1997)
	*185	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- $\alpha$ Activation" <u>J. Immunol.</u> 153:5274-5284 (1994)
	*186	Maeda et al., "Production of Human $\alpha$ -interferon in Silkworm Using a Baculovirus Vector" <u>Nature</u> 315:592-594 (June 13, 1985)
	*187	Mage et al., "Preparation of Fab and F(ab') <sub>2</sub> Fragments from Monoclonal Antibodies" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 79-97 (1987)
✓	*188	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
	*189	<del>Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed., IRL Press (1991)</del>
Cut	*190	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
	*191	Mantei et al., "Rabbit $\beta$ -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit $\beta$ -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
	*192	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*193	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	*194	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	*195	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- $\kappa$ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	*196	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- $\kappa$ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
Cut	*197	Marsters et al., "Interferon $\gamma$ Signals Via a High-Affinity Multisubunit Receptor Complex That Contains Two Types of Polypeptide Chain" <u>Proc. Natl. Acad. Sci. USA</u> 92:5401-5405 (1995)
	*198	<del>Martin et al., "Cell-free Reconstitution of Fas-, UV Radiation- and Ceramide-induced Apoptosis" <u>EMBO Journal</u> 14(21):5191-5200 (1995)</del>
all	*199	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K <sup>+</sup> Channel Currents" <u>Science</u> 255:192-194 (1992)
	*200	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)
	*201	Mather et al., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
	*202	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" <u>Methods in Enzymology</u> 65:499-560 (1980)
an	*203	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)

Examiner

Ray M. [Signature]

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |      |   |
|------|---|
| *204 | Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" <u>Nature Genetics</u> 15:146-156 (Feb 1997)   |
| *205 | Messing et al., "A System for Shotgun DNA Sequencing" <u>Nucleic Acids Research</u> 9(2):309-321 (1981)   |
| *206 | Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" <u>Genetic Engineering</u> , Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)  |
| *207 | Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (1983)   |
| *208 | Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)   |
| *209 | Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)  |
| *210 | Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)   |
| *211 | Morrison et al., "Transfer and expression of immunoglobulin genes" <u>Annual Review of Immunology</u> 2:239-256 (1984)  |
| *212 | Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)  |
| *213 | Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" <u>Science</u> 209:1422-1427 (Sep 1980)  |
| *214 | Munro, "Uses of chimaeric antibodies" <u>Nature</u> 312:597 (1984)  |
| *215 | Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)   |
| *216 | Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)   |
| *217 | Nagata et al., "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)   |
| *218 | Nagata, "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)   |
| *219 | NCBI/GenBank EST; Locus AA223122:(computer printout attached)   |
| *220 | NCBI/GenBank EST; Locus AA232440:(computer printout attached)   |
| *221 | NCBI/GenBank EST; Locus HS75A7R:(computer printout attached)  |
| *222 | Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)  |
| *223 | Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990) |

Examiner

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*224	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)
*225	Olsson and Kaplan, "Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5429-5431 (1980)
*226	Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" <u>Molecular &amp; Cellular Biology</u> 4(7):1293-1305 (July 1984)
*227	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)
*228	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)
*229	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
*230	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
*231	Pavlakakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7398-7402 (December 1981)
*232	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>Eur. J. Haematol.</u> 41:414-419 (1988)
*233	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)
*234	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P439) p. 118 (1991)
*235	Peterson, N., "Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies" <u>Laboratory Animal Science</u> 46(1):8-14 (Feb..1996)
*236	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand; a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
*237	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
*238	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
*239	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (February 12, 1987)
*240	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)
*241	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" <u>Euro. Cytokine Network</u> (abstract No. 82) 7:210 (April-Jun 1996)
*242	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" <u>Programmed Cell Death Meeting</u> (abstract only) pps. 127 (20-24 September 1995)
*243	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 $\beta$ Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643 / 1646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- \*244 Remington's Pharmaceutical Sciences, Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)
- \*245 Reyes et al., "Expression of Human  $\beta$ -interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" Nature 297:598-601 (June 17, 1982)
- \*246 Rice and Baltimore, "Regulated expression of an immunoglobulin K gene introduced into a mouse lymphoid cell line" Proc. Natl. Acad. Sci. USA 79:7862-7865 (1982)
- \*247 Riechmann et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (Mar 24, 1988)
- \*248 Rothe et al., "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor" Cell 78:681-692 (1994)
- \*249 Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" Blood 82:15-21 (1993)
- \*250 Sambrook et al. Molecular Cloning: A Laboratory Manual, Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
- \*251 Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" Cell 61:361-370 (April 20, 1990)
- \*252 Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" Proc. Natl. Acad. Sci. USA 83:1881-1885 (1986)
- \*253 Schneider et al., "Characterization of two receptors for TRAIL" FEBS Letters 416:329-334 (1997)
- \*254 Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" Current Biology 7:693-696 (1997)
- \*255 Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor  $\alpha$  inhibitor" Journal of Biological Chemistry 264:11966-11973 (1989)
- \*256 Sharon et al., "Expression of a  $V_H C_K$  chimaeric protein in mouse myeloma cells" Nature 309:364-367 (1984)
- \*257 Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" Gene 23:315-330 (1983)
- \*258 Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" Science 277:818-821 (1997)
- \*259 Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity" Journal of Immunology 148(9):2918-2922 (May 1, 1992)
- \*260 Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" Cell 20:269-281 (June 1980)
- \*261 Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" Cell 89:309-319 (Apr 18, 1997)
- \*262 Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" The Journal of Immunology 151(4):2296-2308 (Aug 1993)
- \*263 Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" Journal of Biological Chemistry 266:14163-14166 (1991)

Examiner

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643/1646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*264	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (May 25, 1990)
*265	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. &amp; Biophys. Res. Comm.</u> 176:335-342 (1991)
*266	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" <u>Cell</u> 76:959-962 (1994)
*267	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry &amp; Biophysics</u> 259(1):52-57 (1987)
*268	Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" <u>J. Molec. Appl. Genet.</u> 1:327-341 (1982)
*269	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
*270	Steinitz et al., "EB virus-induced B lymphocyte cell lines producing specific antibody" <u>Nature</u> 269(5627):420-422 (Sep 29, 1977)
*271	Steller, "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)
*272	Stevenson et al., "A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge" <u>Anti-Cancer Drug Design</u> 3(4):219-230 (Mar 1989)
*273	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)
*274	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)
*275	Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" <u>Molecular &amp; Cellular Biology</u> 5:410-413 (1985)
*276	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
*277	Suva et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" <u>Science</u> 237(4817):893-896 (Aug. 1987)
*278	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
*279	Tartaglia et al., "A novel domain within the 55kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)
*280	Tewari et al., "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)
*281	Tewari et al., "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
*282	Tewari et al., "Yama/CPP32 $\beta$ , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)
*283	Thomas et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)

Examiner

Clair M. Kuf

Date Considered

3/12/83

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

22	*284	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)
	*285	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)
22	*286	Thotakura et al., "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)
	*287	<del>Tissue Culture, Kruse and Patterson; eds., New York: Academic Press (1973)</del>
22	*288	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)
	*289	Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" <u>Nature</u> 339:68-70 (1989)
	*290	Tschumper et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)
	*291	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
	*292	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-29 (1987)
	*293	Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)
	*294	Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" <u>Bio/Technology</u> 8:135-139 (1990)
	*295	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)
	*296	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)
	*297	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)
	*298	Verma et al., "Rel/NF- $\kappa$ B/I $\kappa$ B Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
	*299	von Bulow et al., "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (Oct 3, 1997)
	*300	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)
	*301	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" <u>Nature</u> 356:314-317 (1992)
	*302	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)
22	*303	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)

Examiner

Date Considered

3/12/83

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce  
Patent and Trademark Office

P1101P2

09/396,710

## Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

~~1643~~ 1644

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |      |  |
|------|--|
| *304 | Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London Ser A</u> 317:415-423 (1986)  |
| *305 | Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)  |
| *306 | Wolff et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice" <u>Cancer Research</u> 53(11):2560-2565 (Jun 1, 1993)   |
| *307 | Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997)                  |
| *308 | Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (October 1997)   |
| *309 | Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)  |
| *310 | Yaniv, M., "Enhancing Elements for Activation of Eukaryotic Promoters" <u>Nature</u> 297(6):17-18 (May 1982)   |
| *311 | Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)              |
| *312 | Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)   |
| *313 | Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987)   |
| *314 | Zoller et al., "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982) |

Examiner

Date, Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce  
Patent and Trademark Office

P1101P2

09/396,710

(Use several sheets if necessary)

Ashkenazi et al.

15 Sep 1999

Group

## U.S. PATENT DOCUMENTS

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

Group  
~~1643~~ 1646

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>Cur</i>	1	WO 00/66156	09.11.00	PCT	<del>          </del>			

[illegible]

Date Considered  
3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CUH	1	6,046,048	04.04.00	Ashkenazi et al.			

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>AW</i>	2	WO 98/51793	19.11.98	PCT				
<i>AW</i>	3	WO 98/58062	23.12.98	PCT				

[illegible]

Clair M. K.

3/12/03

USCOMM-DC 80-398.

ATTY. DOCKET NO.  
P1101P2

SERIAL NO.  
09/396,710

**APPLICANTS**  
Ashkenazi et al.

FILING DATE  
September 15, 1999

GROUP  
1646

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

590558

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group 1

1646

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
an	1	08/799,861					13.02.97
	2	08/815,255					12.03.97
	3	08/820,364		Gearing			12.03.97
	4	08/829,536					28.03.97
	5	08/843,651		Holtzman			16.04.97
	6	08/843,652		Holtzman			16.04.97
	7	08/853,684					09.06.97
	8	08/869,852					04.06.97
	9	08/883,036					26.06.97
	10	08/916,625					08.08.97
	11	09/042,583					17.03.98
	12	09/565,009					14.05.00
	13	09/712,726		Gearing			14.11.00
	14	2002/0048566	25.04.02	El-Deiry et al.			13.09.01
	15	2002/0048785	25.04.02	Holtzman			
	16	2002/0072091	13.06.02	Ni et al.			
	17	2002/0098550	25.07.02	Ni et al.			
	18	2002/0160446	31.10.02	Holtzman			
	19	5,763,223	09.06.98	Wiley et al.			
	20	6,313,269	06.11.01	Deen et al.			
	21	6,455,262	24.09.02	Cox et al.			
	22	60/040,846					17.03.97
	23	60/041,230					14.03.97
	24	60/054,021					29.07.97
	25	60/132,498					04.05.99
	26	60/133,238					07.05.99
	27	60/148,939					13.08.99

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
cmk	*28	510,691	28.10.92	EPO				
in	*29	870,827	14.10.98	EPO				
an	30	WO 00/77191		PCT				
an	31	WO 02/053727	11.07.02	PCT				
an	32	WO 92/01047	23.01.92	PCT				
an	33	WO 92/20791	26.11.92	PCT				

Examiner

Clair M. Kay

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1646

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
CUK	34	WO 93/00109	07.01.93	PCT				
	35	WO 93/06213	01.04.93	PCT				
	36	WO 93/11236	10.06.93	PCT				
	37	WO 93/19172	30.09.93	PCT				
	38	WO 95/01438	12.01.95	PCT				
	39	WO 95/15388	08.06.95	PCT				
	*40	WO 98/35986,	20.08.98	PCT				
	*41	WO 98/41629	24.09.98	PCT				
	*42	WO 98/46643	22.10.98	PCT				
	*43	WO 99/02653	21.01.99	PCT				
CUK	*44	WO 99/09165	25.02.99	PCT				
	*45	WO 99/11791	11.03.99	PCT				
	*46	WO 99/12963	18.03.99	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CUK	47	Carter et al., "Antibody Engineering Using Very Long Template-Assembled Oligonucleotides" <u>Methods: A Companion to Methods in Enzymology</u> 3(3):183-192 (Dec 1991)
	48	Chapman, "A Region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas" <u>B.S. Chapman/FEBS Letters</u> 374:216-220 (1995)
CUK	49	<u>Handbook of Monoclonal Antibodies</u> , Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
	50	Hoogenboom, "Designing and optimizing library selection strategies for generating high-affinity antibodies" <u>Trends in Biotechnology</u> 15(2):62-70 (Feb 1997)
CUK	51	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> (NIH Publ. No. 91-3242), 5th edition
	52	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)
CUK	53	Neri et al., "Engineering recombinant antibodies for immunotherapy" <u>Cell Biophysics</u> 27(1):47-61 (Aug 1995)
	54	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology.</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)
CUK	55	Rabidezh et al., "Induction of Apoptosis by the Low-Affinity NGF Receptor" <u>Science</u> 261:345-348 (1993)
	56	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)
CUK	57	Soderlind et al., "Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems" <u>Immunological Reviews</u> 130:109-124 (Dec 1992)
	58	Winter et al., "Making antibodies by phage display technology" <u>Annual Review of Immunology</u> 12:433-455 (1994)

Examiner

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1646

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>CML</i>	1	6,417,328	09.07.02	Alnemri			

Examiner

*Clawson*

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.